Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria
Jazyk angličtina Země Německo Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
29119254
DOI
10.1007/164_2017_72
Knihovny.cz E-zdroje
- Klíčová slova
- Heme, High-throughput screening, Homocysteine, Protein misfolding, Pyridoxal-5′-phosphate, S-adenosylmethionine,
- MeSH
- cystathionin-beta-synthasa chemie nedostatek fyziologie MeSH
- homocystinurie farmakoterapie MeSH
- lidé MeSH
- molekulární chaperony terapeutické užití MeSH
- posttranslační úpravy proteinů MeSH
- rychlé screeningové testy MeSH
- sbalování proteinů MeSH
- stabilita enzymů MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- cystathionin-beta-synthasa MeSH
- molekulární chaperony MeSH
Classical homocystinuria (HCU) is the most common loss-of-function inborn error of sulfur amino acid metabolism. HCU is caused by a deficiency in enzymatic degradation of homocysteine, a toxic intermediate of methionine transformation to cysteine, chiefly due to missense mutations in the cystathionine beta-synthase (CBS) gene. As with many other inherited disorders, the pathogenic mutations do not target key catalytic residues, but rather introduce structural perturbations leading to an enhanced tendency of the mutant CBS to misfold and either to form nonfunctional aggregates or to undergo proteasome-dependent degradation. Correction of CBS misfolding would represent an alternative therapeutic approach for HCU. In this review, we summarize the complex nature of CBS, its multi-domain architecture, the interplay between the three cofactors required for CBS function [heme, pyridoxal-5'-phosphate (PLP), and S-adenosylmethionine (SAM)], as well as the intricate allosteric regulatory mechanism only recently understood, thanks to advances in CBS crystallography. While roughly half of the patients respond to treatment with a PLP precursor pyridoxine, many studies suggested usefulness of small chemicals, such as chemical and pharmacological chaperones or proteasome inhibitors, rescuing mutant CBS activity in cellular and animal models of HCU. Non-specific chemical chaperones and proteasome inhibitors assist in mutant CBS folding process and/or prevent its rapid degradation, thus resulting in increased steady-state levels of the enzyme and CBS activity. Recent interest in the field and available structural information will hopefully yield CBS-specific compounds, by using high-throughput screening and computational modeling of novel ligands, improving folding, stability, and activity of CBS mutants.
Department of Anesthesiology University of Texas Medical Branch Galveston TX USA
Department of Pediatrics School of Medicine University of Colorado Aurora CO USA
Department of Physical Chemistry University of Granada Granada Spain
Citace poskytuje Crossref.org
A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase